Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With CancerKevin C. Conlon, Thomas A. Waldmann, Thomas A. Fleisher et al.|Journal of Clinical Oncology|2014Cited by 714
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A. Waldmann, Stephen P. Creekmore, Enrico Lugli et al.|Blood|2011Cited by 194
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C. Conlon, Thomas A. Waldmann, E. Lake Potter et al.|Clinical Cancer Research|2019Cited by 134